Filing Details
- Accession Number:
- 0001209191-19-059179
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-04 19:47:02
- Reporting Period:
- 2019-12-02
- Accepted Time:
- 2019-12-04 19:47:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1346830 | Cara Therapeutics Inc. | CARA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1166287 | T Derek Chalmers | C/O Cara Therapeutics, Inc. 4 Stamford Plaza, 107 Elm St, 9Th Floor Stamford CT 06902 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-12-02 | 10,000 | $25.79 | 918,468 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-12-02 | 20,000 | $0.00 | 938,468 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2019-12-04 | 10,699 | $17.05 | 927,769 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.612 to $25.885, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 2, 2019. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (3), and does not represent a discretionary trade by the Reporting Person.
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above.
Billionaire Hedge Funds
